{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:21:13Z","timestamp":1778977273069,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.iac.2024.07.003","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T11:29:45Z","timestamp":1723807785000},"page":"629-644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis"],"prefix":"10.1016","volume":"44","author":[{"given":"Ejiofor","family":"Ezekwe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Weskamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke M.","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy D.","family":"Klion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.iac.2024.07.003_bib1","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.7326\/0003-4819-68-6-1220","article-title":"The hypereosinophilic syndromes","volume":"68","author":"Hardy","year":"1968","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.iac.2024.07.003_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.iac.2024.07.003_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2024.07.003_bib4","first-page":"277","article-title":"Allergic granulomatosis, allergic angiitis, and periarteritis nodosa","volume":"27","author":"Churg","year":"1951","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.iac.2024.07.003_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00005792-198403000-00001","article-title":"Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome","volume":"63","author":"Lanham","year":"1984","journal-title":"Medicine (Baltim)"},{"issue":"8","key":"10.1016\/j.iac.2024.07.003_bib6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.iac.2024.07.003_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.iac.2024.07.003_bib8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1398-9995.2012.02873.x","article-title":"Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome","volume":"67","author":"Khoury","year":"2012","journal-title":"Allergy"},{"issue":"Suppl 117","key":"10.1016\/j.iac.2024.07.003_bib9","first-page":"40","article-title":"Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma","volume":"37","author":"Pagnoux","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.iac.2024.07.003_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.iac.2024.07.003_bib11","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.iac.2024.07.003_bib12","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2024.07.003_bib13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2024.07.003_bib14","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.07.003_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2024.07.003_bib16","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.iac.2024.07.003_bib17","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.jaip.2022.04.037","article-title":"Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5","volume":"10","author":"Rothenberg","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2024.07.003_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1035250","article-title":"Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome","volume":"10","author":"Roufosse","year":"2023","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.iac.2024.07.003_bib19","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2024.07.003_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.iac.2024.07.003_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00509-2023","article-title":"Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics","volume":"10","author":"Jayne","year":"2024","journal-title":"ERJ Open Research"},{"issue":"7","key":"10.1016\/j.iac.2024.07.003_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/acr2.11571","article-title":"Clinical benefit of mepolizumab in eosinophilic granulomatosis with polyangiitis for patients with and without a vasculitic phenotype","volume":"5","author":"Terrier","year":"2023","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"10.1016\/j.iac.2024.07.003_bib23","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2024.07.003_bib24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.iac.2024.07.003_bib25","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2024.07.003_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.iac.2024.07.003_bib27","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"14","key":"10.1016\/j.iac.2024.07.003_bib28","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2024.07.003_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.222","article-title":"Long-term Efficacy and Safety of Benralizumab Treatment for PDGFRA-negative Hypereosinophilic Syndrome","volume":"153","author":"Kuang","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.07.003_bib30","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"17","key":"10.1016\/j.iac.2024.07.003_bib31","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iac.2024.07.003_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/cells10010019","article-title":"Discovery, Function, and Therapeutic Targeting of Siglec-8","volume":"10","author":"Youngblood","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.iac.2024.07.003_bib33","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le","year":"2020","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.iac.2024.07.003_bib34","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"26","key":"10.1016\/j.iac.2024.07.003_bib35","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10209","key":"10.1016\/j.iac.2024.07.003_bib36","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.iac.2024.07.003_bib37","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.iac.2024.07.003_bib38","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.iac.2024.07.003_bib39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2024.07.003_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia Induced by Blocking the IL-4\/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.07.003_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacig.2022.03.006","article-title":"Eosinophilic granulomatosis with polyangiitis after treatment with dupilumab","volume":"1","author":"Yamazaki","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Glob"},{"issue":"3","key":"10.1016\/j.iac.2024.07.003_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003300","article-title":"Eosinophilic granulomatosis polyangiitis (EGPA) complicated with periaortitis, precipitating role of dupilumab? A case report a review of the literature","volume":"9","author":"Kai","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.iac.2024.07.003_bib43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12890-023-02415-6","article-title":"Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report","volume":"23","author":"Suzaki","year":"2023","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.iac.2024.07.003_bib44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdcr.2022.03.017","article-title":"Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome","volume":"29","author":"Du","year":"2022","journal-title":"JAAD Case Reports"},{"issue":"10","key":"10.1016\/j.iac.2024.07.003_bib45","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1016\/j.jaip.2021.06.033","article-title":"Effect of dupilumab treatment in a severe asthma patient with EGPA","volume":"9","author":"Matucci","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2024.07.003_bib46","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1093\/rheumatology\/kead479","article-title":"Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis","volume":"63","author":"Caminati","year":"2024","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.iac.2024.07.003_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.214","article-title":"Dupilumab Use in Patients with Hypereosinophilic Syndrome: A Multi-Center Case Series","volume":"153","author":"Ezekwe","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2024.07.003_bib48","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1136\/ard-2023-224756","article-title":"Dupilumab for relapsing or refractory sinonasal and\/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study","volume":"82","author":"Molina","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.iac.2024.07.003_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094369","article-title":"Tezepelumab: A potential new biological therapy for severe refractory asthma","volume":"22","author":"Pelaia","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.iac.2024.07.003_bib50","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2024.07.003_bib51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/all.15609","article-title":"Sounding the alarmins-The role of alarmin cytokines in asthma","volume":"78","author":"Gauvreau","year":"2023","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.iac.2024.07.003_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143366","article-title":"A\u00a0role for IL-33-activated ILC2s in eosinophilic vasculitis","volume":"6","author":"Kotas","year":"2021","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.iac.2024.07.003_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102737","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review","volume":"20","author":"Akiyama","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.iac.2024.07.003_bib54","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.iac.2024.07.003_bib55","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jaip.2020.12.066","article-title":"Remission of cold-agglutinin autoimmune hemolytic anemia and hypereosinophilic syndrome with rituximab therapy","volume":"9","author":"Wetzler","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2024.07.003_bib56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.iac.2024.07.003_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"9842","key":"10.1016\/j.iac.2024.07.003_bib58","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.iac.2024.07.003_bib59","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaip.2022.02.006","article-title":"An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes","volume":"10","author":"Chen","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.07.003_bib60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.iac.2024.07.003_bib61","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: A network analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2024.07.003_bib62","article-title":"Exacerbation of eosinophilic granulomatosis with polyangiitis after administering dupilumab for severe asthma and eosinophilic rhinosinusitis with nasal polyposis","volume":"14","author":"Tanaka","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.iac.2024.07.003_bib63","doi-asserted-by":"crossref","DOI":"10.1186\/ar4066","article-title":"Th17 expansion in granulomatosis with polyangiitis (Wegener\u2019s): the role of disease activity, immune regulation and therapy","volume":"14","author":"Wilde","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.iac.2024.07.003_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000905","article-title":"Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"5","author":"Teixeira","year":"2019","journal-title":"RMD Open"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:39:35Z","timestamp":1728391175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856124000523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0889856124000523"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2024.07.003","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2024.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}